Gilead Sciences, Inc. is keeping close watch on the turbulence in India over its antiviral, remdesivir, licensed to several local firms, as the country grapples with severe shortages of the therapy and cases of black marketing amid a sharp surge in COVID-19 cases.
There have also been calls for compulsory licensing of remdesivir, while the Indian government has stepped in to fast-track additional production sites and at the same time seemingly nudged
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?